News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
AstraZeneca PLC Lung Cancer Pill May Get Second Chance After Tests
November 21, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Nov 20 (Reuters) - The lung cancer pill Iressa has shown surprising results for patients with advanced disease where it has been at least as effective as a standard chemotherapy treatment, researchers reported on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
AstraZeneca
MORE ON THIS TOPIC
FDA
FDA’s cell and gene therapy head steps down after 1 year
June 30, 2026
·
2 min read
·
Michael Gibney
Regulatory
FDA hits Praxis with 3-month delay for epilepsy drug verdict
June 30, 2026
·
2 min read
·
Tristan Manalac
Regulatory
Amgen’s Tavneos troubles continue as
NEJM
retracts pivotal publication
June 30, 2026
·
2 min read
·
Tristan Manalac
Cancer
Replimune gets early August decision date for twice-rejected melanoma drug
June 26, 2026
·
3 min read
·
Tristan Manalac